Mkts

CytomX Therapeutics, Inc.

NASDAQ: CTMX
$2.19+0.05 (+2.34%)
As of Nov 6, 4:00 PM ET

Key statistics

Day range
2.122.27
52-week range
2.118.21
Today
Open2.24
Previous close2.19
Volume—
Valuation
Market cap477.20M
P/E ratio—
EPS (TTM)-0.44
Income & risk
Dividend / yield—
Beta2.41
Avg volume3.55M
Discussion

CTMX News

Stories mentioning CTMX from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ1 '26Mar 31Q4 '25Dec 31Q3 '25Sep 30Q2 '25Jun 30Q1 '25Mar 31Q4 '24Dec 31Q3 '24Sep 30Q2 '24Jun 30
Income Statement
Revenue10,258663.005,96318,65850,91738,09333,43225,115
Cost of Goods Sold
Gross Profit
Operating Expenses
Research & Development19,23821,23415,30413,32218,86814,79021,36825,172
Sales General & Admin
Total Operating Expenses29,93028,59421,73119,94428,29620,41429,32133,567
Operating Income (Loss)(19,672)(27,931)(15,768)(1,286)22,62117,6794,111(8,452)
Interest Income1,4901,4811,5921,178955.001,2781,6931,971
Interest Expense
Other Expense(7.00)(5.00)5.0017.0011.00(18.00)(7.00)(2.00)
Pretax Income(18,189)(26,455)(14,171)(91.00)23,58718,9395,797(6,483)
Tax Provision59.0055.0058.0063.0062.0063.0061.0051.00
Net Income (Loss)(18,248)(26,510)(14,229)(154.00)23,52518,8765,736(6,534)
Earnings Per Share (Basic)(0.19)0.22
Earnings Per Share (Diluted)(0.19)0.22
Weighted Average Shares Outstanding (Basic)177,273137,936165,004129,07687,12284,43985,09384,881
Weighted Average Shares Outstanding (Diluted)177,273137,936165,004129,07687,15184,74585,20584,881

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About CTMX

CytomX Therapeutics, Inc. (NASDAQ: CTMX) is a stock listed on the Nasdaq Stock Market under the ticker symbol CTMX. It last traded at $2.19 (Nov 6, 2026, 4:00 PM ET), up 2.3% on the day. That gives CytomX Therapeutics a market capitalisation of $477.2M.

Over the past 52 weeks CTMX has traded between $2.11 and $8.21.

Revenue for the quarter ended Mar 31, 2026 was $10.3M; a net loss of $18.2M. Revenue was down 79.9% from $50.9M in the quarter ended Mar 31, 2025.

Last 4 quarters
Quarter endedRevenueNet incomeMargin
Mar 31, 2026$10.3M-$18.2M-177.9%
Dec 31, 2025$663.0K-$26.5M-3998.5%
Sep 30, 2025$6.0M-$14.2M-238.6%
Jun 30, 2025$18.7M-$154.0K-0.8%

From CytomX Therapeutics’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…